Ocrelizumab makes strong showing in OPERA studies
MSF offices closed for Independence Day
A new study casts doubt on MS indicators
Multiple Sclerosis Coalition taps Skutnik to lead
Supreme Court upholds Obamacare
Sandoz launches Glatopa, the first generic competitor to Copaxone
Cleaved cell fragments possible MS marker
Unless otherwise specified, all medical content is compiled by MSF staff and reviewed for accuracy by a member of our Medical Advisory Board.
The MSF strives to present clear and unbiased information. This site is partially funded through a grant from Bayer Healthcare, LLC.
Website Design by SimplexWeb
© Copyright 2000-2013 Multiple Sclerosis Foundation - All Rights Reserved